India, Dec. 24 -- The prevalence of chronic kidney disease (CKD) in India is estimated at around 13.24%, with a sharp increase reported in recent years. Anaemia remains one of the most common complica-tions of CKD, affecting over 70% of patients and significantly impacting quality of life and survival. At the same time, the dialysis population in India continues to grow by 10 to 20 percent each year. The Indian Society of Nephrology (ISN) has released its updated 2025 guidelines for the management of anaemia in CKD, marking the first comprehensive revision since 2013. Over the past decade, clinical practice has evolved with the availability of newer therapies, including erythropoiesis-stimulating agents (ESAs), hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs), improved iron management strategies, and advances in diagnostics and monitoring. These developments, combined with India-specific challenges such as a high diabetes burden, resource constraints, and affordability considerations. Dr HS Kohli, President of the Indian Society of Nephrology, said, "The release of the ISN Guidelines for Chronic Kidney Disease management marks a major milestone. These recommendations aim to standardise treatment protocols and simplify clinical decision-making for everyday practice." Dr Shyam Bihari Bansal, Secretary of the Indian Society of Nephrology, added, "A key highlight is the emphasis on anaemia management, with darbepoetin identified as the preferred option for both dialysis and non-dialysis CKD patients." Dr Vivekanand Jha, Editor of the Indian Journal of Nephrology, said, "We pleased to publish the ISN 2025 guidelines for the management of anaemia of CKD in India and other resource-constrained settings. The guidelines offer practical and actionable recommendations that support consistent, resource-sensitive, patient-centred care....